The US Food and Drug Administration granted approval for Life Biosciences to start a clinical study testing a gene‑therapy approach designed to reverse cellular aging markers. The greenlight permits the company to initiate an early‑phase trial that will evaluate safety and biomarkers tied to cellular 'age' in human subjects. The decision puts a controversial aging‑reversal hypothesis into a formal clinical pathway and marks one of the few regulatory endorsements for therapies explicitly aimed at modifying molecular aging signatures. The program will focus on safety and mechanistic readouts before any efficacy claims can be pursued in larger cohorts. Clarification: 'Cellular reprogramming' or 'age‑rewinding' refers to interventions intended to restore youthful gene‑expression or epigenetic patterns in adult cells rather than replacing tissues.